Alternative assay formats to identify diverse inhibitors of protein kinases

Expert Opinion on Drug Discovery

Volumn 3, Issue 7, 2008, Pages 819-831

  Singh, Pirthipal ^a   Ward, Walter H J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Allosteric; Assay technology; ATP competitive; Binding; High throughput screening; Hit identificafion; Inhibitor; Kinase assay; Protein kinase

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PURINE; SORAFENIB; SUNITINIB;

AMPLIFIED LUMINESCENCE PROXIMITY HOMOGENEOUS ASSAY; ASSAY; ATP DEPLETION ASSAY; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CALIPER; CATALYSIS; DISSOCIATION ENHANCED LANTHANIDE FLUORESCENCE IMMUNOASSAY; DRUG DESIGN; DRUG DETERMINATION; DRUG TARGETING; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FILTER CAPTURE ASSAY; FLASHPLATE; FLUORESCENCE RESONANCE ENERGY TRANSFER; IMMOBILIZED METAL ASSAY FOR PHOSPHOCHEMICAL; IRON QUENCH; OMNIA; PATENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW; SCINTILLATION PROXIMITY ASSAY; TRANSCREENER;

EID: 48049114377     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.7.819     Document Type: Review

References (51)

1. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34
2. Stoeckli K, Haag H. High-throughput screening. Chapter 8. In: Rang HP, editor, Drug discovery and development (Technology in transition). Churchill Livingstone Elsevier Publishers; 2006. p. 99-119
3. Cohen P. Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1(4):309-15
4. Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell 1996;85(2):149-58
5. Zhuang SF, Zhou CH, Qian J, et al. A new model for random screening inhibitors of vascular endothelial growth factor receptor 1 kinase. Acta Pharmacol Sin 2002;23(2):117-23
6. Waddleton D, Ramachandran C, Wang QP. Developments of a time-resolved fluorescent assay for measuring tyrosine-phosphorylated proteins in cells. Anal Biochem 2002;309(1):150-7
7. Evans DB, Rank KB, Sharma SK. A scintillation proximity assay for studying inhibitors of tau protein kinase II/cdk5 using a 96-well format. J Biochem Biophys Methods 2002;50(2-3):151-61
8. Xu K, Stern AS, Levin W, et al. A generic time-resolved fluorescence assay for serine/threonine kinase activity: application to Cdc7/Dbf4. J Biochem Mol Biol 2003;36(4):421-5
9. Guenat S, Rouleau N, Bielmann C, et al. Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates. J Biomol Screen 2006;11(8):1015-26
10. Cherry M, Williams DH. Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr Med Chem 2004;11(6):663-73
11. Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112(6):859-71
12. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1(7):493-502
13. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289(5486):1938-42
14. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9(4):268-72
15. Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
16. Manley PW, Bold G, Brüggen J, et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 2004;1697(1-2):17-27
17. Hasegawa M, Nishigakin N, Washio Y, et al. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem 2007;50(18):4453-70
18. Sullivan JE, Holdgate GA, Campbell D, et al. Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase. Biochemistry 2005;44(50):16475-90
19. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
20. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4(12):937-47
21. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11(12):1192-7
22. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351(1):95-105
23. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64(18):6652-9
24. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-82
25. McCaulry TJ, Stanaitis ML, Dean SM, et al. IQ technology: development of a universal, homogeneous method for high throughput screening and phosphatase activity. J Assoc Lab Automation 2003;8(2):36-40
26. Singh P, Lillywhite B, Bannaghan C, et al. Using IMAP technology to identify kinase inhibitors: comparison with a substrate depletion approach and analysis of the nature of false positives. Comb Chem High Throughput Screen 2005;8:319-25
27. Jenkins WT. The pyruvate-coupled assay for ATPases: a critical analysis. Anal Biochem 1991;194(1):136-9
28. Togame H, Fuchikami K, Sagara A, et al. Development of a non-radioactive, 384-well format assay to detect inhibitors of the mitogen-activated protein kinase kinase 4. Assay Drug Dev Technol 2005;31:65-76
29. Singh P, Harden BJ, Lillywhite BJ, et al. Identification of kinase inhibitors by an ATP depletion method. Assay Drug Dev Tech 2004;2(2):161-9
30. Available from: http://www.berthold-ds.com (PKLight assay, developed by Cambrex)
31. Available from: http://www.promega.com (Kinase-Glo™, from Promega)
32. Available from: http://www.biothema.com (Kinase reaction rate kit, from BioThema)
33. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005;385(2):399-408
34. Davidson W, Frego L, Peet GW, et al. Discovery and characterization of a substrate selective p38alpha inhibitor. Biochemistry 2004;43(37):11658-71
35. Lu Z, Yin Z, James L, et al. Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase. J Biomol Screen 2004;9:309-21
36. Available from: http://www.discoverx.com (HitHunter™ EFC Kutase Assays, DiscoveRx)
37. Vainshtein I, Silveria S, Kaul P, et al. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP™). J Biomol Screen 2002;7(6):507-14
38. Available from: http://www.corning.com_tm (Epic™ System, Corning™)
39. Available from: http://www.srubiosystems.com (BIND Reader™, SRU Biosystems)
40. Cooper MA. Optical biosensors: where next and how soon? Drug Discov Today 2006;11(23/24):1061-7
41. Cooper MA. Non-optical screening platforms: the next wave in label-free screening? Drug Discov Today 2006;11(23/24):1068-74
42. Gill A, Cleasby A, Jhoti H. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. Chembiochem 2005;6(3):506-12
43. Adrián FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2(2):95-102
44. Hangauer D, Gelman D, Dyster L, et al. Potent and selective in vitro and in vivo inhibition of tumor proliferation by KX01, a novel non-ATP competitive Src inhibitor [abstract 3245]. Proc Am Cancer Res 2007;48
45. Barr RK, Boehm I, Attwood PV, et al. The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J Biol Chem 2004;279(35):36327-38
46. Niu L, Chang KC, Wilson S, et al. Kinetic characterization of human JNK2alpha2 reaction mechanism using substrate competitive inhibitors. Biochemistry 2007;46(16):4775-84
47. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007;12(15-16):622-33
48. Kamath L. Maximising discovery using kinase assays. Genetic Engineering News 2006;26(18):1
49. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluating and validation of high-throughput screening assays. J Biomol Screen 1999;4:67-73
50. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446(7132):153-8
51. Burgess MR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102(9):3395-400